HEDIS MY2026 Year-End Sprint: How ACOs Can Close Critical Quality Gaps Before December 31

November 15, 2026

Six weeks. That's what separates every ACO, MSO, and physician group from HEDIS MY2026 year-end lock. The measurement year closes December 31, and if your attributed population's quality measure performance doesn't move before then, it won't move until 2028 performance reporting cycles—if it moves at all.

This isn't a planning conversation. It's an execution conversation. And the gap between ACOs that finish MY2026 strong and those that don't almost never comes down to data quality or care gap identification. It comes down to whether your team can convert a gap list into a completed encounter before December 31.

Why MY2026 Has Higher Stakes Than Usual

HEDIS MY2026 runs under updated NCQA specifications that tightened numerator criteria on several high-weight measures, including Controlling High Blood Pressure (CBP) and Hemoglobin A1c Control for Patients with Diabetes (HBD). Meanwhile, CMS's expanding use of AI-based utilization review—confirmed by the Senate's July 2026 vote preserving the WISeR model—means care team bandwidth is tighter than it was in MY2024 or MY2025. Prior authorization friction is higher, documentation requirements are more intensive, and care managers are carrying more on their plates during the same Q4 sprint window.

MSSP ACOs in Enhanced Track face a compound problem: HEDIS-adjacent quality measures contribute directly to shared savings calculations in some quality scoring methodologies, and the final push on AWV completion, colorectal screening, and diabetes care control affects both HEDIS composite rates and risk adjustment accuracy simultaneously. Missing the December 31 deadline doesn't just hurt a quality score—it delays the revenue impact until the following performance year.

The Five Measures With the Highest ROI in the Next Six Weeks

Not every HEDIS measure is closeable in six weeks. Breast Cancer Screening (BCS) requires a mammogram to have occurred—you cannot retroactively complete that in December. But several high-weight measures are both influenceable and completable in a short window:

1. Annual Wellness Visit (AWV)

AWV completion remains the single highest-leverage activity in Q4 for most ACOs. A completed AWV addresses multiple HEDIS and Star Rating elements simultaneously: depression screening, fall risk assessment, advance care planning, and cognitive assessment. Every completed AWV in November–December moves the needle across four to six measures at once.

At PBACO, Zynix-driven outreach increased AWV completion rates by 34% over baseline within a single performance quarter by automatically identifying attributed patients without a calendar-year AWV, ranking them by proximity to practices with open slots, and running a multi-touch voice and text outreach campaign. The limiting factor was never the gap list—it was converting that list into scheduled encounters at scale. For the full billing requirements, see our guide on AWV billing: G0438 vs G0439, required elements and eligibility for 2026.

2. Colorectal Cancer Screening (COL)

Colonoscopy has a 10-year lookback, but stool-based tests (FIT, FIT-DNA) must be completed within the measurement year. If your COL rate is below 60% and you have attributed patients between 46–75 who haven't completed any qualifying test, mailing FIT kits with return postage—paired with a voice outreach reminder—can close 15–20% of open gaps in four to six weeks. This is one of the most cost-effective Q4 moves in outpatient VBC.

3. A1c Control for Patients with Diabetes (HBD)

HBD measures the percentage of diabetic patients with an A1c result in the measurement year—not necessarily a controlled A1c, just a completed test. Any attributed diabetic patient without an A1c result since January 1, 2026 is an open gap closeable with a lab order and a completed draw before December 31. This is pure workflow: identify the gap list, outreach, order, complete.

4. Controlling High Blood Pressure (CBP)

CBP requires a blood pressure reading below 140/90 documented in the measurement year. For patients with hypertension who haven't had an office visit since Q1, a brief telehealth check-in with a documented BP reading can close the gap. The challenge is that many hypertensive patients in a managed population are also high-utilization—meaning care managers already know who they are but haven't had bandwidth to close the encounter.

5. Medication Adherence for Diabetes and Hypertension (MDA/MHY)

Both measures require a proportion of days covered (PDC) ≥ 80% for the measurement year. Patients currently at 65–79% PDC are reachable before year-end. The math: a patient at 68% PDC on November 1 needs approximately 50 consecutive adherence days to cross 80% by December 31. Pharmacy-coordinated outreach now—not December 15—is what moves this measure.

The Operational Gap: Why Identification Isn't the Problem

Every ACO using a population health platform can produce a HEDIS gap list. What most cannot produce is a systematic conversion workflow that turns a gap list into a completed encounter without manual care manager intervention on every record.

The math is brutal at scale. If your attributed population is 8,000 patients and 22% have a closeable HEDIS gap before year-end, that's 1,760 patients. If your care team can personally outreach 60 patients per week, you close roughly 300 gaps by December 31—17% of what's possible.

AI-driven outreach changes the denominator. At HCN, Zynix scaled care management workflows across a 23,000-patient attributed population with no additional FTE hires by deploying AI agents for the initial outreach tier—automated voice and text campaigns that escalate to human care managers only when the patient has a clinical question or scheduling barrier. The result was a 4.2x increase in outreach volume with the same care team headcount.

At CHOA, managing a pediatric population with significant preventive care gaps, AI-assisted outreach for well-child visits and developmental screening closed 29% of open preventive gaps before the measurement year end—a result that required no additional staff, only better prioritization and automated first-contact volume.

This is the execution problem in HEDIS Q4: not knowing who needs what, but converting that knowledge into action at a volume your team cannot achieve manually. For a detailed look at how AI-driven gap closure works operationally, see how AI closes care gaps: from identification to resolution.

The Six-Week Playbook

Weeks 1–2: Launch and Prioritize (Now Through November 29)

Pull your current gap list segmented by measure and by practice. Prioritize AWV, COL stool-based, and HBD lab completion—these are the fastest to close with outreach alone. Run your first outreach wave for all three simultaneously. Any FIT kits that need to go out must be mailed by November 20 to allow return processing time before December 31.

Weeks 3–4: Close First Wave and Escalate (December 1–14)

Convert scheduled AWV appointments and lab completions from wave one. Escalate non-responders. This is also the window for CBP telehealth check-ins for hypertensive patients. For MDA/MHY, run your pharmacy outreach now—patients have three weeks to get back on a consistent refill schedule before the threshold locks.

Weeks 5–6: Final Closings Only (December 15–31)

No new outreach campaigns started after December 15 will generate closeable encounters by year-end. This window is for scheduling reschedules, documentation confirmations, and ensuring your EHR data feeds your quality registry in near-real-time so completed encounters are reflected immediately in your gap tracking.

At Union Health, coordinating across three primary care sites for HEDIS MY2025, this structured Q4 sprint added 6.3 points to their overall diabetes composite rate before lock—a difference that qualified them for a higher quality bonus tier under their commercial VBC contracts.

What to Do if Your Team Cannot Execute This at Scale

The honest constraint for most ACOs in November is bandwidth. Care managers are already running TCM workflows from November discharges, annual HCC recapture, and routine CCM check-ins. Adding a HEDIS Q4 sprint without additional capacity produces the same result every year: about 15–20% of possible gaps close, and the opportunity cost is absorbed silently.

The question isn't whether you should do a Q4 quality sprint. It's whether you have the operational infrastructure to run one at the volume that actually moves composite rates. For the right role delineation between care managers and AI agents in this structure, see our breakdown of care management vs case management: differences, roles and where AI helps.

At Eternal Health, managing a dual-eligible population where HEDIS and Stars performance directly ties to plan revenue, Zynix's AI outreach agents ran the initial contact tier for all five priority measures simultaneously across 4,100 attributed patients in the first week of November—a campaign that would have taken three care managers six weeks to run manually.

If you're running an ACO, MSO, or value-based contract and you're heading into December tracking less than 55% AWV completion, less than 58% colorectal screening completion, or more than 20% of your attributed diabetic population without a 2026 A1c on file — the window to close those gaps is weeks, not months.

Gautam Chowdhary (CTO & Co-founder) personally takes a handful of 15-minute intro calls each week. No slide deck — just your 3 hardest VBC operational problems and whether Zynix can close the gap in under 60 days.

Book a free care gap opportunity analysis: zynix.ai/cclf-opportunity-analysis

Explore More Insights

Visit Our Blog